INTRODUCTION
response to hormone therapy and chemotherapy. As a matter of fact; estrogen receptor status is regarded at present as the most powerful predictive marker in breast cancer management (7) .
Estrogen and progesterone receptors are co-dependent variables, progesterone receptor (PR) being a weaker predictor of hormone receptor response to endocrine therapy than estrogen receptor (ER For recurrent breast cancer and assessment of loco-regional lymph node metastases, FDG-PET was compared mainly with MRI.
Hathaway et al. compared FDG-PET and
MRI in ten patients with clinical suspicion of recurrent loco-regional breast cancer.
Nine patients had evidence of loco 
Diagnosis of metastatic lesions:
There is evidence that FDG-PET has great potential in tumor staging (Fig 1) (Table 3) . Table 3 . FDG-PET in the evaluation of tumor response in metastatic disease.
Monitoring therapy of metastatic disease is difficult, since tissue sampling is not feasible; earlier response assessment could be beneficial to guide further therapy and avoid prolonged treatment with ineffective drugs; CT or MRI is still the standard method to assess treatment, but anatomic changes occur too late in order to assess early treatment response (morphological changes shown by radiological methods take 2-3 months to show evidence); metabolic changes occur much earlier and can be easily assessed with PET Treatment of metastatic disease SUV, standardized uptake value Van der Hiel, et al 2001 (47) . 
